Please ensure Javascript is enabled for purposes of website accessibility

U.K. Regulatory Advisor Rejects Roche Cancer Drug

By Eric Volkman - Feb 26, 2020 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NICE recommended that the country's National Health Service not prescribe Polivy.

Roche Holdings (RHHBY 0.91%) has suffered a sales setback for a drug in its cancer portfolio. On Wednesday, the U.K.'s National Institute for Health and Care Excellence (NICE) published an appraisal of Polivy (polatuzumab vedotin) in which it chose not to recommend that the country's National Health Service prescribe the treatment. 

NICE is the highly influential advisory arm of the U.K. government's Department of Health.

Red and white blood cells.

Image source: Getty Images

Polivy is intended to be used in combination with Roche's Rituxan and the chemotherapy bendamustine to treat patients with relapsed/refractory diffuse large B-cell lymphoma, a relatively rare type of blood cancer. Polivy won accelerated approval for that use by the Food and Drug Administration last June.

At the time, Roche emphasized the need for a more effective drug to use as part of a combination to fight this type of cancer. "Despite meaningful progress in the treatment of diffuse large B-cell lymphoma, treatment options are very limited when the disease is refractory to or recurrent after multiple regimens," the company wrote in a press release.

In January, Polivy received conditional marketing approval from the European Medicines Agency, the pharmaceutical industry regulator for the European Union. It was designated an orphan medicine by that agency due to the nature of the disease.

NICE's recommendation will put more pressure on Roche to shore up its oncology portfolio. Three of the company's cancer treatments -- Rituxan, Avastin, and Herceptin -- now face competition from biosimilars, and their sales have declined as a result.

Roche's stock was up in late Wednesday trading, but only marginally. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (0.91%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.